Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $184

Benzinga Newsdesk www.benzinga.com Positive 85.5%

Neg 0% Neu 0% Pos 85.5%

Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $160 to $184.